摘要
2018年1月至2022年6月期间, 30例难治/复发急性髓系白血病(R/R AML)患者在河南省肿瘤医院接受MeCBA方案(司莫司汀+克拉屈滨+白消安+阿糖胞苷)增强预处理挽救性异基因造血干细胞移植(allo-HSCT)。30例患者中男16例, 女14例, 中位年龄37(16~53)岁。同胞全相合供者移植3例, 无关供者移植1例, 单倍体移植26例。移植前中位化疗疗程数为4(3~22)个。移植后粒细胞、血小板植入中位时间分别为14(9~22)d 、18(10~40)d , 移植后30 d粒细胞累积植入率为100%, 移植后100 d血小板累积植入率为96.7%(95%CI 85.4%~97.5%)。22例(73.3%)患者出现1~2级胃肠道不良反应, 未出现3~4级脏器毒性。中位随访37.1个月, 移植后3年总生存率为70.0%(95%CI 50.3%~83.1%), 无事件生存率为65.3%(95%CI 44.8%~79.8%), 累积复发率为21.2%(95%CI 9.2%~44.4%), 非复发死亡率为16.7%(95%CI 7.3%~35.5%)。
Thirty refractory relapsed acute myeloid leukemia(R/R AML)patients who received salvage allo-HSCT with MeCBA conditioning regimen from January 2018 to June 2022 at Henan Cancer Hospital were included,and their clinical data were reviewed.There were 16 males and 14 females among the 30 patients with a median age of 37(16-53)years.There were 3 sibling allograft donor transplants,1 unrelated donor transplant,and 26 haplotype transplants.The median course of pre-transplant chemotherapy was 4(3-22).The time of neutrophil engraftment was 14(9-22)days and 18(10-40)days for platelet.The 30-day cumulative incidence of neutrophil engraftment was 100%and the 100-day cumulative incidence of platelet engraftment was 96.7%(95%CI 85.4%-97.5%).22(73.3%)patients experienced grade 1-2 gastrointestinal reactions,and there was no grade 3-4 organ toxicity.With a median follow-up of 37.1 months,the overall survival(OS)rate,event-free survival(EFS)rate,cumulative recurrence rate(CIR),and non-recurrence mortality(NRM)rate at 3 years after transplantation were 70.0%(95%CI 50.3%-83.1%),65.3%(95%CI 44.8%-79.8%),21.2%(95%CI 9.2%-44.4%)and 16.7%(95%CI 7.3%-35.5%),respectively.
作者
袁芳芳
王勇奇
李明会
李钢苹
李子夜
米瑞华
尹青松
符粤文
魏旭东
Yuan Fangfang;Wang Yongqi;Li Minghui;Li Gangping;Li Ziye;Mi Ruihua;Yin Qingsong;Fu Yuewen;Wei Xudong(Department of Hematology,Henan Cancer Hospital/The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2024年第5期500-504,共5页
Chinese Journal of Hematology
基金
国家自然科学基金(82170151)
河南省医学科技攻关计划(LHGJ20220186、LHGJ20220187、SBGJ202102069、232102310201)。